News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,667 Results
Type
Article (14239)
Company Profile (281)
Press Release (253147)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79523)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50459)
Employer Resources (31)
FDA (5721)
Job Trends (5132)
News (144423)
Policy (10031)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21667)
ALS (63)
Alzheimer's disease (845)
Antibody-drug conjugate (ADC) (98)
Approvals (5746)
Artificial intelligence (122)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (51)
Brain cancer (20)
Breast cancer (150)
Cancer (1426)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (112)
Cell therapy (317)
Cervical cancer (8)
Clinical research (41038)
Collaboration (533)
Compensation (256)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (158)
Cystic fibrosis (76)
Data (1454)
Denatured (11)
Depression (29)
Diabetes (134)
Diagnostics (1297)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (89)
Earnings (29776)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48434)
Executive appointments (449)
FDA (6400)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (496)
Gene editing (93)
Generative AI (10)
Gene therapy (242)
GLP-1 (364)
Government (1078)
Grass and pollen (2)
Guidances (20)
Healthcare (6593)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (90)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (112)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (64)
Interviews (17)
IPO (7269)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (206)
Leadership (3)
Legal (1386)
Liver cancer (32)
Lung cancer (201)
Lymphoma (96)
Machine learning (3)
Management (7)
Manufacturing (136)
MASH (52)
Medical device (2597)
Medtech (2598)
Mergers & acquisitions (6281)
Metabolic disorders (383)
Multiple sclerosis (52)
NASH (13)
Neurodegenerative disease (64)
Neuropsychiatric disorders (25)
Neuroscience (1241)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1663)
Now hiring (22)
Obesity (192)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (54)
Parkinson's disease (119)
Partnered (8)
Patents (125)
Patient recruitment (73)
Peanut (35)
People (25614)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14493)
Phase II (19091)
Phase III (12069)
Pipeline (786)
Policy (44)
Postmarket research (852)
Preclinical (6095)
Press Release (30)
Prostate cancer (59)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (287)
Real estate (1418)
Recruiting (12)
Regulatory (8615)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (58)
Series A (98)
Series B (62)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1455)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1974)
State (1)
Stomach cancer (4)
Supply chain (22)
Tariffs (6)
The Weekly (36)
United States (12936)
Vaccines (211)
Venture capitalists (32)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Today (33)
Last 7 days (366)
Last 30 days (1371)
Last 365 days (19461)
2025 (5845)
2024 (20551)
2023 (22415)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17287)
Australia (2931)
California (3768)
Canada (1121)
China (345)
Colorado (145)
Connecticut (149)
Delaware (97)
Europe (37184)
Florida (455)
Georgia (115)
Idaho (16)
Illinois (226)
India (10)
Indiana (91)
Iowa (2)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (466)
Massachusetts (2984)
Michigan (70)
Minnesota (144)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (943)
New Mexico (12)
New York (1015)
North Carolina (543)
North Dakota (4)
Northern California (1663)
Ohio (111)
Oklahoma (9)
Oregon (21)
Pennsylvania (717)
Puerto Rico (5)
Rhode Island (18)
South America (208)
South Carolina (4)
Southern California (1455)
Tennessee (25)
Texas (436)
Utah (52)
Virginia (76)
Washington D.C. (30)
Washington State (345)
Wisconsin (14)
267,667 Results for "bioaegis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences
March 19, 2025
·
3 min read
Business
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
September 12, 2024
·
3 min read
Pharm Country
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
BioAegis Therapeutics is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin for the treatment of Acute Respiratory Distress Syndrome .
February 27, 2024
·
4 min read
Press Releases
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
October 17, 2024
·
4 min read
Pharm Country
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
October 16, 2023
·
4 min read
Pharm Country
BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases
BioAegis Therapeutics, Inc. announces that it will host a free webinar on the expanding spectrum of auto- and hyper- inflammatory diseases on Tuesday, May 23, 2023 at 2:00 pm Eastern Time.
May 10, 2023
·
5 min read
Pharm Country
BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes
BioAegis Therapeutics, Inc. announces publication of two new research studies exploring gelsolin’s role in type 2 diabetes, an inflammation-related metabolic disease.
April 13, 2023
·
4 min read
Pharm Country
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, reports 2022 highlights.
January 6, 2023
·
4 min read
FDA
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
BioAegis Therapeutics, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for recombinant plasma gelsolin to proceed for the treatment of acute respiratory distress syndrome (ARDS).
January 26, 2023
·
4 min read
Pharm Country
BioAegis Therapeutics Highlights Recent Article on its Novel Host-Directed Protein, Plasma Gelsolin, for Inflammatory Diseases
BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory diseases based on a portfolio built around gelsolin technology, announces a new article on its novel host-directed approach.
December 5, 2022
·
2 min read
1 of 26,767
Next
